The present invent addresses the problem of providing a medicine for treating amyotrophic lateral sclerosis, a disease for which there is currently no effective therapeutic agent, and provides a therapeutic agent for amyotrophic lateral sclerosis that contains a growth hormone secretagogue receptor (GHS-R) agonist or a pharmaceutically acceptable salt thereof. The therapeutic agent for amyotrophic lateral sclerosis contains a GHS-R agonist such as ghrelin and is for administration to an individual who is suffering from amyotrophic lateral sclerosis and who does not exhibit severe dysphagia. The individual may be an individual who is unresponsive or insufficiently responsive to existing therapeutic agents for ALS.
